IMU

0.00%

4.8¢ imugene limited

Media Thread, page-15713

First 15713 Last

Share
Profile

Follow
Hittman

2,872 Posts.

251

05/10/24

10:24

Post #: 75989799
Share

Originally posted by Ragnarolf ↑

Thanks Davybabyk,

I had to wait until the weekend to get the time to listen in full. Very informative, helps us understand oncolytic viruses better.

I have held concerns that CF33 in the MAST trial thus far hasn't preformed how we would have hoped (to be a treatment of all solid tumours). Dr Fongs final comments (59:30) all but confirms this for me. "A lot of the patients who have been on a chemotherapy a long time. I'm not convinced their immune systems will do the final job". Whilst expressing his hope he'll have a T cell therapy option in the not too distant future to use in combination (Imugene - onCARlytics).

I am very curious to see how the phase 1 B trial for CF33 in Bile Duct cancer as mono therapy plays out.
He made it clear he wasn't running the MAST trial (out licenced to a company - IMU). Though he said they were enrolling quickly in the Bile Duct expansion and that he had not seen any of the results to date.

Unusual that he kept referencing the MAST phase 1B expansion into Bile Duct cancer as "Phase 2" (multiple times, in text, and never corrected). Seems a rookie mistake for him.

Conclusion for me;
I feel the MAST study has now served its purpose. CF 33 is safe in humans, its able to replicate and spread through the tumour environment, and dependant of the health and strength of the patients immune system it can also show some efficiency in treating and kill cancer cells. Beyond that though it will never succeed as mono therapy through clinical trials in very sick patients (much like Hervaxx).
Not much point spending more money on it and enrolling more cohorts. Time to figure out else works best with CF33 in combination. Looks like T cell therapy is our lead candidate.

Onwards and upwards for onCARlytics and Azercel then. Explains to me why the original MAST trial environments stalled around December 2023.

DYOR - Not Advice

Expand

Leslie has referred 1b as a type of phase 2 in the past.

IMU Price at posting: 4.8¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 6 more messages in this thread...

First 15713 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$328.5K	6.792M

Buyers (Bids)

No.	Vol.	Price($)
45	5443565	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	2171910	5

View Market Depth

No.	Vol.	Price($)
36	4613688	0.048
36	4066646	0.047
46	3070983	0.046
60	6170008	0.045
11	1951364	0.044

Price($)	Vol.	No.
0.049	1200533	2
0.050	4130537	15
0.051	6179811	13
0.052	2579418	10
0.053	1158504	8

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMU (ASX) Chart

Media Thread, page-15713

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media Thread, page-15713

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News